Patent US4331648A successfully refreshed from Google Patents.
US4331648A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N-Acetyl-cysteine protects against cardiac damage from subsequently-administered cardio-toxic anthra-cycline in cancer therapy
Assignee: United States Department of Health and Human Services
•
Filing: 1980-09-23
•
Granted: 1982-05-25
•
Expires: 2000-09-23
Abstract
Abstract The cardiac damage, occurring after treatment with an anthracycline, such as adriamycin, is prevented when N-acetyl-cysteine is orally administered about one hour prior to the treatment with the anthracycline.
Inventors
- 👤 Charles E. Myers, Jr.
- 👤 James H. Doroshow
- 👤 Gershon Y. Locker
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 19:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/185; A61K31/19; A61K31/195
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
67 words
A method of protecting a cancer patient being treated for antitumor purposes with a therapeutically acceptable and effective amount of a cardio-toxic anthracycline drug against usually-ensuing cardiac damage without affecting tumor response or delivery of the drug to cardiac tissue sites, comprising orally administering a range of from 750 mg to 2 grams per kg of N-acetyl-cysteine to a patient undergoing therapy with a cardio-toxic anthracycline drug.
Claim 2
Independent Claim
67 words
A method of protecting a cancer patient being treated for antitumor purposes with a therapeutically acceptable and effective amount of a cardio-toxic anthracycline drug against usually-ensuing cardiac damage without affecting tumor response or delivery of the drug to cardiac tissue sites, comprising orally administering a range of from 750 mg to 2 grams per kg of N-acetyl-cysteine to a patient undergoing therapy with a cardio-toxic anthracycline drug.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the anthracycline drug is adriamycin.
Claim 4
Dependent Claim
11 words
The method of claim 1 wherein the anthracycline drug is daunomycin.
Claim 5
Dependent Claim
21 words
The method of claim 1 wherein the dosage of N-acetyl-cysteine administered is 2 grams of N-acetyl-cysteine per kilogram of body weight.
Claim 6
Dependent Claim
27 words
The method of claim 1 wherein the dosage of N-acetyl-cysteine administered is 5 grams of N-acetyl-cysteine per square meter of the surface area of the human body.
Claim 7
Dependent Claim
20 words
The method of claim 1 wherein the N-acetyl-cysteine is administered about 1 hour prior to the administration of the anthracycline.
Claim 8
Dependent Claim
46 words
The method of claim 1 wherein the anthracycline is adriamycin, the dosage of N-acetyl-cysteine administered is 5 grams of N-acetyl-cysteine per square meter of the surface area of the human body, and the N-acetyl-cysteine is administered about 1 hour prior to the administration of the adriamycin.
Claim 9
Dependent Claim
11 words
The method of claim 1 wherein the anthracycline drug is rubidazone.
Claim 10
Dependent Claim
11 words
The method of claim 1 wherein the anthracycline drug is carminomycin.
Claim 11
Dependent Claim
11 words
The method of claim 1 wherein the anthracycline drug is 7-con-O-methylnogarol.
References Cited (Backward Citations)
US4267163A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-05-24 | 1985-11-23 | 1986-05-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-05-24 | 1989-11-23 | 1990-05-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-05-24 | 1993-11-23 | 1994-05-25 | $7700.00 | Window Closed / Lapsed |